These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34743199)

  • 1. CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles.
    Aitamer M; Akil H; Vignoles C; Branchaud M; Abraham J; Gachard N; Feuillard J; Jauberteau MO; Shirvani H; Troutaud D; Bentayeb H
    Br J Cancer; 2021 Dec; 125(12):1687-1698. PubMed ID: 34743199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas.
    Dubanet L; Bentayeb H; Petit B; Olivrie A; Saada S; de la Cruz-Morcillo MA; Lalloué F; Gourin MP; Bordessoule D; Faumont N; Delage-Corre M; Fauchais AL; Jauberteau MO; Troutaud D
    Br J Cancer; 2015 Sep; 113(6):934-44. PubMed ID: 26284337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
    [No Abstract]   [Full Text] [Related]  

  • 4. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
    Jiang D; Mo Q; Sun X; Wang X; Dong M; Zhang G; Chen F; Zhao Q
    Cancer Sci; 2021 Sep; 112(9):3585-3597. PubMed ID: 34252986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous neurotrophins and Trk signaling in diffuse large B cell lymphoma cell lines are involved in sensitivity to rituximab-induced apoptosis.
    Bellanger C; Dubanet L; Lise MC; Fauchais AL; Bordessoule D; Jauberteau MO; Troutaud D
    PLoS One; 2011; 6(11):e27213. PubMed ID: 22076137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
    Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
    Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of the tumor‑derived extracellular vesicles carrying the miR‑125b‑5p target TNFAIP3 in reducing the sensitivity of diffuse large B cell lymphoma to rituximab.
    Zhang L; Zhou S; Zhou T; Li X; Tang J
    Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33887878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
    [No Abstract]   [Full Text] [Related]  

  • 9. Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
    Hayashi K; Nagasaki E; Kan S; Ito M; Kamata Y; Homma S; Aiba K
    Cancer Sci; 2016 May; 107(5):682-9. PubMed ID: 26920337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.
    Thomsen EA; Rovsing AB; Anderson MV; Due H; Huang J; Luo Y; Dybkaer K; Mikkelsen JG
    Mol Oncol; 2020 Sep; 14(9):1978-1997. PubMed ID: 32585766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of CD20 and PD-L1 levels on small extracellular vesicles (sEV) produced by DLBCL cells and EBV-transformed B cells, and potential role in T cell inhibition.
    Akil H; Bentayeb H; Aitamer M; Vignoles C; Abraham J; Gachard N; Olivrie A; Guyot A; Gobbo J; Feuillard J; Shirvani H; Troutaud D
    Exp Hematol Oncol; 2024 May; 13(1):53. PubMed ID: 38760788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
    Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
    Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.
    Tokunaga T; Tomita A; Sugimoto K; Shimada K; Iriyama C; Hirose T; Shirahata-Adachi M; Suzuki Y; Mizuno H; Kiyoi H; Asano N; Nakamura S; Kinoshita T; Naoe T
    Cancer Sci; 2014 Jan; 105(1):35-43. PubMed ID: 24147568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping.
    Carvalho AS; Baeta H; Henriques AFA; Ejtehadifar M; Tranfield EM; Sousa AL; Farinho A; Silva BC; Cabeçadas J; Gameiro P; Silva MGD; Beck HC; Matthiesen R
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.
    Li YJ; Li ZM; Rao HL; Xia Y; Huang HQ; Xia ZJ; Li S; Li WY; Jiang WQ
    J Transl Med; 2012 May; 10():84. PubMed ID: 22554077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.